Revenues Not Telling The Story For Everest Medicines Limited (HKG:1952)

There wouldn't be many who think Everest Medicines Limited's (HKG:1952) price-to-sales (or "P/S") ratio of 14x is worth a mention when the median P/S for the Biotechs industry in Hong Kong is similar at about 13.5x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

See our latest analysis for Everest Medicines

How Has Everest Medicines Performed Recently?

Recent times have been advantageous for Everest Medicines as its revenues have been rising faster than most other companies. One possibility is that the P/S ratio is moderate because investors think this strong revenue performance might be about to tail off. If not, then existing shareholders have reason to be feeling optimistic about the future direction of the share price.

Keen to find out how analysts think Everest Medicines' future stacks up against the industry? In that case, our free report is a great place to start.

How Is Everest Medicines' Revenue Growth Trending?

In order to justify its P/S ratio, Everest Medicines would need to produce growth that's similar to the industry.

Taking a look back first, we see that the company grew revenue by an impressive 103% last year. The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance. Therefore, it's fair to say the revenue growth recently has been superb for the company.

Shifting to the future, estimates from the six analysts covering the company suggest revenue should grow by 63% per annum over the next three years. Meanwhile, the rest of the industry is forecast to expand by 87% per annum, which is noticeably more attractive.

In light of this, it's curious that Everest Medicines' P/S sits in line with the majority of other companies. It seems most investors are ignoring the fairly limited growth expectations and are willing to pay up for exposure to the stock. Maintaining these prices will be difficult to achieve as this level of revenue growth is likely to weigh down the shares eventually.

The Final Word

Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

When you consider that Everest Medicines' revenue growth estimates are fairly muted compared to the broader industry, it's easy to see why we consider it unexpected to be trading at its current P/S ratio. At present, we aren't confident in the P/S as the predicted future revenues aren't likely to support a more positive sentiment for long. This places shareholders' investments at risk and potential investors in danger of paying an unnecessary premium.

Many other vital risk factors can be found on the company's balance sheet. Our free balance sheet analysis for Everest Medicines with six simple checks will allow you to discover any risks that could be an issue.

If these risks are making you reconsider your opinion on Everest Medicines, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.